STOCK TITAN
  1. Home
  2. News
  3. OPK

OPKO Health, Inc. - $OPK STOCK NEWS

Welcome to our dedicated page for OPKO Health news (Ticker: $OPK), a resource for investors and traders seeking the latest updates and insights on OPKO Health stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OPKO Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OPKO Health's position in the market.

News
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. The company's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 3rd beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. A webcast of the call can also be accessed at OPKO’s Investor Relations page. A telephone replay and webcast replay will be available after the completion of the live conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
conferences earnings
-
News
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Rhea-AI Summary
Pfizer and OPKO Health announce FDA approval for NGENLA, a once-weekly treatment for children with growth hormone deficiency. NGENLA is expected to be available for prescribing in the US in August 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
fda approval
-
News
OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
Rhea-AI Summary
OPKO Health, Inc. reports Q1 2023 financial results and business highlights. Highlights include a collaboration agreement with Merck, sales of NGENLA® by Pfizer, and BioReference Health's new dual-stain triage test. Q1 revenue increased in Pharmaceuticals, while Diagnostics revenue decreased due to lower COVID-19 testing volume. Consolidated total revenues decreased compared to Q1 2022. Operating loss decreased, and net loss included non-cash income. Cash and cash equivalents were $110.8 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
earnings
News
OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences earnings
-
News
OPKO Health to Hold Virtual R&D Day on March 20, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
none
-
News
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
News
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
earnings
-
News
OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
conferences earnings
-
News
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
News
OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
Stock OPK logo
OPKO Health, Inc.

Nasdaq:OPK

OPK Rankings

#2528 Ranked by Market Cap
#4112 Ranked by Stock Gains
N/A Ranked by Dividends

OPK Stock Data

920.03M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIAMI

About OPK

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig